Thrombocytosis

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

NCT00882414 | PHASE 2 | INTERVENTIONAL

The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.

1 Sites

26 Participants

Recruiting

18 Years to 60 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Univ. clinic for Internal Medicine

Vienna,Austria,1090

Study Eligibility Criteria

Inclusion Criteria

* Male or female, inpatient or outpatient, aged at least 18 years and not more than 60 years.
* Have a platelet count \>450G/l
* Transferrin saturation (TfS) \<20% or ferritin \< 100µg/l
* Previously diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis)
* Females of child-bearing potential must have a negative urine pregnancy test at screening and be practicing a highly effective method of birth control during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. Non-childbearing potential includes being surgically sterilized at least 6 months prior to the study or postmenopausal, defined as amenorrhoea for at least 12 months.
* Demonstrate the ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to undergo the required assessments.

Exclusion Criteria

* CDAI \>220, CAI\>6
* Significant anemia (hemoglobin \<10.5 g/dl), or anaemia not caused by iron deficiency (e.g. anaemia due to cancer or infection)
* Blood transfusions or iron therapy during the previous 4 weeks, or erythropoietin treatment within the 8 weeks prior to enrollment.
* Concomitant therapy with prednisolone above 20mg/d, 6-mercaptopurine, infliximab or azathioprine must have been initiated at least 4 months prior to study and the dose must be stable for at least 8 weeks. Other drugs with known effects on megakaryopoiesis (e.g. interferon-alpha).
* Severe concomitant disease or need for surgery within 8 weeks
* Hemochromatosis or other iron-storage disorders (e.g. thalassemia, siderosis, lead poisoning anaemia, porphyria cutanea tarda)
* Treatment with an investigational drug within the 30 days prior to enrollment
* Active severe infection or malignancy other than carcinoma in situ of the cervix and non-melanoma skin cancer.
* Bone Marrow Disease (MDS, thalassemia, etc)
* Active or chronic liver or kidney disease. Serum albumin \<25 g/L or serum creatinine \>20 mg/L
* Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgment of the investigator. Known hypersensitivity to FERINJECT®
* Positive for HIV 1/HIV 2 antibodies (anti HIV) (HIV: human immunodeficiency virus).
* Positive for hepatitis B surface-antigen (HBsAg), hepatitis C virus antibody (anti HCV) and evidence for active hepatitis, i.e., abnormal liver function test (LFT) results.

Additional Studies

Additional studies can be found at ClinicalTrials.gov